Mina Nabil Kamel

Dr. Mina Nabil Kamel

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 December 2020 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Ahmed MostafaAhmed Mostafa
Ahmed Mostafa
Ahmed KandeilAhmed Kandeil
Ahmed Kandeil
YEYaseen Elshaier
Yaseen Elshaier
OKOmnia Kutkat
Omnia Kutkat
YMYassmin Moatasim
Yassmin Moatasim
NCNational Centre
National Centre
(1) Background: Drug repositioning is an unconventional drug discovery approach to explore new therapeutic benefits of existing drugs. Currently, it emerges as a rapid avenue to alleviate the COVID-19 pandemic disease. (2) Methods: Herein, we tested the antiviral activity of anti-microbial and anti-inflammatory Food and Drug Administration (FDA)-approved drugs, commonly prescribed to relieve respiratory symptoms, against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the viral causative agent of the COVID-19 pandemic. (3) Results: Of these FDA-approved antimicrobial drugs, Azithromycin, Niclosamide, and Nitazoxanide showed a promising ability to hinder the replication of a SARS-CoV-2 isolate, with IC50 of 0.32, 0.16, and 1.29 µM, respectively. We provided evidence that several antihistamine and anti-inflammatory drugs could partially reduce SARS-CoV-2 replication in vitro. Furthermore, this study showed that Azithromycin can selectively impair SARS-CoV-2 replication, but not the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). A virtual screening study illustrated that Azithromycin, Niclosamide, and Nitazoxanide bind to the main protease of SARS-CoV-2 (Protein data bank (PDB) ID: 6lu7) in binding mode similar to the reported co-crystalized ligand. Also, Niclosamide displayed hydrogen bond (HB) interaction with the key peptide moiety GLN: 493A of the spike glycoprotein active site. (4) Conclusions: The results suggest that Piroxicam should be prescribed in combination with Azithromycin for COVID-19 patients.

28 May 2020 in Microbiology Resource Announcements
Verified
Journal Article
Open access
PDF file
Ahmed KandeilAhmed Kandeil
Ahmed Kandeil
Ahmed MostafaAhmed Mostafa
Ahmed Mostafa
Rabeh El-SheshenyRabeh El-Shesheny
Rabeh El-Shesheny
MSMahmoud M. Shehata
Mahmoud M. Shehata
WRWael H Roshdy
Wael H Roshdy
MAMohamed A Ali
Mohamed A Ali
This report announces the complete genome sequences of two severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) isolates detected in Egypt. The isolates were obtained from oropharyngeal swab specimens from two Egyptians in Upper and Lower Egypt. Sequence analysis showed mutations that differentiate Egyptian strains from the reference strain 2019-nCoV WHU01.

26 December 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
Rabeh El-SheshenyRabeh El-Shesheny
Rabeh El-Shesheny
YMYassmin Moatasim
Yassmin Moatasim
SMSara H. Mahmoud
Sara H. Mahmoud
YSYi Song
Yi Song
ATAhmed El Taweel
Ahmed El Taweel
NCNational Centre
National Centre
Clade 2.3.4.4 H5Nx influenza viruses have further diversified into several subclades. Sub-clade 2.3.4.4b H5N1 viruses have been widely circulating in wild birds and detected in Europe, Africa, Asia, and North America since October 2020. In this study, we report the first detection of highly pathogenic avian influenza H5N1 clade 2.3.4.4b viruses in wild birds and domestic ducks from live bird markets in Egypt. Phylogenetic analysis revealed that the Egyptian H5N1 virus retained the genomic composition of Eurasian strains. Mutations in the viral proteins associated with zoonotic potential and pathogenicity were detected in Egyptian isolates. Egypt is considered a hot spot for the evolution of the influenza virus, so active surveillance of avian influenza viruses in Egypt is warranted.

3 March 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
Ahmed KandeilAhmed Kandeil
Ahmed Kandeil
Ahmed MostafaAhmed Mostafa
Ahmed Mostafa
RHRehab R. Hegazy
Rehab R. Hegazy
Rabeh El-SheshenyRabeh El-Shesheny
Rabeh El-Shesheny
ATAhmed El Taweel
Ahmed El Taweel
MAMohamed A. Ali
Mohamed A. Ali
Since the emergence of SARS-CoV-2 at the end of 2019, 64 candidate vaccines are in clinical development and 173 are in the pre-clinical phase. Five types of vaccines are currently approved for emergency use in many countries (Inactivated, Sinopharm; Viral-vector, Astrazeneca, and Gamaleya Research Institute; mRNA, Moderna, and BioNTech/Pfizer). The main challenge in this pandemic was the availability to produce an effective vaccine to be distributed to the world’s population in a short time. Herein, we developed a whole virus NRC-VACC-01 inactivated candidate SARS-CoV-2 vaccine and tested its safety and immunogenicity in laboratory animals. In the preclinical studies, we used four experimental animals (mice, rats, guinea pigs, and hamsters). Antibodies were detected as of week three post vaccination and continued up to week ten in the four experimental models. Safety evaluation of NRC-VACC-01 inactivated candidate vaccine in rats revealed that the vaccine was highly tolerable. By studying the effect of booster dose in the immunological profile of vaccinated mice, we observed an increase in neutralizing antibody titers after the booster shot, thus a booster dose was highly recommended after week three or four. Challenge infection of hamsters showed that the vaccinated group had lower morbidity and shedding than the control group. A phase I clinical trial will be performed to assess safety in human subjects.

11 March 2021 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
MGMokhtar Gomaa
Mokhtar Gomaa
ARAmira S. El Rifay
Amira S. El Rifay
MSMahmoud M. Shehata
Mahmoud M. Shehata
Ahmed KandeilAhmed Kandeil
Ahmed Kandeil
MKMina Nabil Kamel
Mina Nabil Kamel
NCNational Centre
National Centre
SARS-CoV-2 virus is transmitted in closed settings to people in contact with COVID-19 patients such as healthcare workers and household contacts. However, household person-to-person transmission studies are limited. Households participating in an ongoing cohort study of influenza incidence and prevalence in rural Egypt were followed. Baseline enrollment was done from August 2015 to March 2017. The study protocol was amended in April 2020 to allow COVID-19 incidence and seroprevalence studies. A total of 290 households including 1598 participants were enrolled and followed from April to October 2020 in four study sites. When a participant showed respiratory illness symptoms, a serum sample and a nasal and an oropharyngeal swab were obtained. Swabs were tested by RT-PCR for SARS-CoV-2 infection. If positive, the subject was followed and swabs collected on days three, six, nine, and 14 after the first swab day and a serum sample obtained on day 14. All subjects residing with the index case were swabbed following the same sampling schedule. Sera were collected from cohort participants in October 2020 to assess seroprevalence. Swabs were tested by RT-PCR. Sera were tested by Microneutralization Assay to measure the neutralizing antibody titer. Incidence of COVID-19, household secondary attack rate, and seroprevalence in the cohort were determined. The incidence of COVID-19 was 6.9% and the household secondary attack rate was 89.8%. Transmission within households occurred within two-days of confirming the index case. Infections were asymptomatic or mild with symptoms resolving within 10 days. The majority developed a neutralizing antibody titer by day 14 post onset. The overall seroprevalence among cohort participants was 34.8%. These results suggest that within-household transmission is high in Egypt. Asymptomatic or mild illness is common. Most infections seroconvert and have a durable neutralizing antibody titer.

30 August 2024 in Emerging Microbes & Infections
Verified
Journal Article
Open access
OKOmnia Kutkat
Omnia Kutkat
MGMokhtar Gomaa
Mokhtar Gomaa
YMYassmin Moatasim
Yassmin Moatasim
ATAhmed El Taweel
Ahmed El Taweel
MKMina Nabil Kamel
Mina Nabil Kamel
Rabeh El-SheshenyRabeh El-Shesheny
Rabeh El-Shesheny
Avian influenza viruses (AIVs) pose continuous challenges to human and animal health worldwide. Wild birds are considered the natural reservoir for AIVs and play a major role in spreading influenza...